PL2613798T3 - Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów - Google Patents

Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów

Info

Publication number
PL2613798T3
PL2613798T3 PL11758644T PL11758644T PL2613798T3 PL 2613798 T3 PL2613798 T3 PL 2613798T3 PL 11758644 T PL11758644 T PL 11758644T PL 11758644 T PL11758644 T PL 11758644T PL 2613798 T3 PL2613798 T3 PL 2613798T3
Authority
PL
Poland
Prior art keywords
acid lipase
lysosomal acid
patients
treatment
lysosomal
Prior art date
Application number
PL11758644T
Other languages
English (en)
Other versions
PL2613798T5 (pl
Inventor
Anthony Quinn
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45806910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2613798(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2011/033699 external-priority patent/WO2011133960A2/en
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of PL2613798T3 publication Critical patent/PL2613798T3/pl
Publication of PL2613798T5 publication Critical patent/PL2613798T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL11758644T 2010-09-09 2011-09-09 Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów PL2613798T5 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40301110P 2010-09-09 2010-09-09
US45601410P 2010-10-29 2010-10-29
US201161432372P 2011-01-13 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme
PCT/US2011/051096 WO2012050695A1 (en) 2010-09-09 2011-09-09 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP11758644.6A EP2613798B2 (en) 2010-09-09 2011-09-09 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients

Publications (2)

Publication Number Publication Date
PL2613798T3 true PL2613798T3 (pl) 2015-07-31
PL2613798T5 PL2613798T5 (pl) 2018-06-29

Family

ID=45806910

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11758644T PL2613798T5 (pl) 2010-09-09 2011-09-09 Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
PL14200334T PL2977057T3 (pl) 2010-09-09 2011-09-09 Izolowana rekombinowana ludzka lizosomalna N-glikozylowana kwaśna lipaza

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14200334T PL2977057T3 (pl) 2010-09-09 2011-09-09 Izolowana rekombinowana ludzka lizosomalna N-glikozylowana kwaśna lipaza

Country Status (30)

Country Link
US (6) US8663631B2 (pl)
EP (3) EP3650039B1 (pl)
JP (3) JP5693728B2 (pl)
KR (1) KR20150038636A (pl)
CN (2) CN105457018A (pl)
AR (1) AR082953A1 (pl)
AU (1) AU2011314293B2 (pl)
BR (2) BR122019021757B1 (pl)
CA (2) CA2810999C (pl)
CL (1) CL2013000664A1 (pl)
CO (1) CO6710913A2 (pl)
CY (1) CY1116544T1 (pl)
DK (2) DK2977057T3 (pl)
ES (3) ES3074107T3 (pl)
HK (2) HK1220907A1 (pl)
HR (1) HRP20150438T1 (pl)
HU (1) HUE048688T2 (pl)
IL (2) IL225095A (pl)
ME (1) ME02062B (pl)
MX (2) MX365007B (pl)
NZ (3) NZ700824A (pl)
PL (2) PL2613798T5 (pl)
PT (2) PT2977057T (pl)
RS (1) RS53947B1 (pl)
RU (1) RU2550961C2 (pl)
SG (2) SG188456A1 (pl)
SI (2) SI2977057T1 (pl)
SM (1) SMT201500108B (pl)
TW (1) TWI482625B (pl)
WO (1) WO2012050695A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138535D1 (de) * 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
KR101742346B1 (ko) 2010-04-23 2017-06-15 시나게바 바이오파르마, 코포레이션 리소솜 축적병 효소
BR122019021757B1 (pt) * 2010-09-09 2020-12-08 Alexion Pharmaceuticals, Inc composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)
EP2675472A4 (en) * 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
WO2013055888A2 (en) 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof
KR20140130443A (ko) * 2012-03-02 2014-11-10 시나게바 바이오파르마, 코포레이션 절두된 리소좀 산 리파제
CN106885910B (zh) * 2015-12-15 2018-12-21 上海吉涛生物科技有限公司 肿瘤易感微环境检测装置及试剂盒
WO2017218926A1 (en) 2016-06-17 2017-12-21 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
EP3504222A1 (en) 2016-08-23 2019-07-03 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11396499B2 (en) 2018-12-12 2022-07-26 University Of Washington Lysosomal acid lipase assay
WO2021117122A1 (ja) * 2019-12-10 2021-06-17 株式会社リボルナバイオサイエンス ライソゾーム酸性リパーゼ欠損症の予防または治療剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
AU1580292A (en) 1991-03-13 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996004001A1 (en) 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
NZ506214A (en) 1996-09-13 2002-11-26 Transkaryotic Therapies Inc Therapy for alpha-galactosidase A deficiency
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK2020438T3 (en) 1998-12-07 2018-07-23 Genzyme Corp Treatment of Pompe disease
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002221755A1 (en) 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20050181474A1 (en) 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
ES2498369T3 (es) 2002-04-16 2014-09-24 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Un marcador para medir cirrosis hepática
CA2499188A1 (en) 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US8124732B2 (en) * 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US7524626B2 (en) 2005-10-05 2009-04-28 Synageva Biopharma Corp. Rapid production of high titer virus
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US20070267249A1 (en) 2006-05-18 2007-11-22 Cullen David P Roof safety system
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
JP2009541211A (ja) 2006-05-24 2009-11-26 ミエリン リペア ファウンデーション， インコーポレイテッド 血液脳関門の透過性
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
US8466118B2 (en) 2007-04-23 2013-06-18 Saint Louis University Modulation of blood brain barrier protein expression
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
NZ599928A (en) 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of asthma
JP2010533170A (ja) 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子
US20100291060A1 (en) 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a
AU2009204495B2 (en) 2008-01-07 2013-10-24 Synageva Biopharma Corp. Glycosylation in avians
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
EP2448600B1 (en) 2009-07-03 2016-03-30 INSERM - Institut National de la Santé et de la Recherche Médicale Compounds targeting the cation-independent mannose 6-phosphate receptor
US20110033699A1 (en) 2009-07-23 2011-02-10 Nitto Denko Corporation Pressure-sensitive adhesive tape
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
US20150030582A1 (en) 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
KR101742346B1 (ko) 2010-04-23 2017-06-15 시나게바 바이오파르마, 코포레이션 리소솜 축적병 효소
BR122019021757B1 (pt) 2010-09-09 2020-12-08 Alexion Pharmaceuticals, Inc composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
ES2664844T3 (es) 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US20130027021A1 (en) 2011-07-28 2013-01-31 Abb Inc. Current sensor
CN103842517A (zh) 2011-08-03 2014-06-04 莲花组织修复公司 胶原蛋白7及相关方法
WO2013055888A2 (en) 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof

Also Published As

Publication number Publication date
CN105457018A (zh) 2016-04-06
PT2613798E (pt) 2015-06-02
KR20150038636A (ko) 2015-04-08
US20160051638A1 (en) 2016-02-25
EP2613798A1 (en) 2013-07-17
ME02062B (me) 2015-05-20
PL2977057T3 (pl) 2020-06-01
ES3074107T3 (es) 2026-07-17
SMT201500108B (it) 2015-07-09
SI2977057T1 (sl) 2020-03-31
US20220362350A1 (en) 2022-11-17
CO6710913A2 (es) 2013-07-15
US11400141B2 (en) 2022-08-02
CL2013000664A1 (es) 2013-10-04
BR122019021757B1 (pt) 2020-12-08
JP5693728B2 (ja) 2015-04-01
DK2613798T4 (en) 2018-04-16
US8663631B2 (en) 2014-03-04
EP2613798B2 (en) 2018-01-24
HUE048688T2 (hu) 2020-08-28
CN103200958A (zh) 2013-07-10
NZ700824A (en) 2016-03-31
JP2015052014A (ja) 2015-03-19
NZ715014A (en) 2018-10-26
ES2535605T5 (es) 2018-04-30
EP2977057B1 (en) 2019-11-06
JP2016145257A (ja) 2016-08-12
ES2769836T3 (es) 2020-06-29
DK2977057T3 (da) 2020-02-10
DK2613798T3 (en) 2015-04-20
EP3650039A1 (en) 2020-05-13
SG188456A1 (en) 2013-04-30
SI2613798T1 (sl) 2015-05-29
BR112013005673A2 (pt) 2017-09-19
US20120064055A1 (en) 2012-03-15
HK1220907A1 (zh) 2017-05-19
EP2977057A1 (en) 2016-01-27
SI2613798T2 (en) 2018-05-31
TW201225971A (en) 2012-07-01
BR112013005673B1 (pt) 2020-12-15
NZ608292A (en) 2014-10-31
RU2013110491A (ru) 2014-11-10
EP2613798B1 (en) 2015-02-11
US20250025538A1 (en) 2025-01-23
IL245283A0 (en) 2016-06-30
CA3209456A1 (en) 2012-04-19
JP6156882B2 (ja) 2017-07-05
EP3650039B1 (en) 2026-04-15
CY1116544T1 (el) 2018-03-07
PL2613798T5 (pl) 2018-06-29
PT2977057T (pt) 2020-02-18
AR082953A1 (es) 2013-01-23
TWI482625B (zh) 2015-05-01
IL225095A (en) 2016-05-31
JP2013540733A (ja) 2013-11-07
CA2810999A1 (en) 2012-04-19
US10166274B2 (en) 2019-01-01
US20140348752A1 (en) 2014-11-27
CA3209456C (en) 2025-05-06
AU2011314293B2 (en) 2015-06-04
SG10201507199UA (en) 2015-10-29
HK1215532A1 (en) 2016-09-02
MX2013002704A (es) 2013-09-13
RS53947B1 (sr) 2015-08-31
IL245283B (en) 2019-02-28
ES2535605T3 (es) 2015-05-13
US12076376B2 (en) 2024-09-03
AU2011314293A1 (en) 2013-04-04
HRP20150438T1 (hr) 2015-05-22
WO2012050695A1 (en) 2012-04-19
US20190282671A1 (en) 2019-09-19
CA2810999C (en) 2023-10-03
RU2550961C2 (ru) 2015-05-20
MX365007B (es) 2019-05-20

Similar Documents

Publication Publication Date Title
PL2613798T5 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
CY2021031I1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
LT2596786T (lt) Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
IL218324B (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
BR112013013684A2 (pt) tratamento das condiçóes mediadas por jak-2
JP2013512229A5 (ja) 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｐｐ−ｉｖ阻害薬による治療
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
DK3162386T3 (da) Implanterbare medicinske indretninger
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
ZA201301601B (en) Treatment of diseases
HRP20180780T1 (hr) Liječenje gihta i hiperurikemije
IL215467A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
PL2627345T3 (pl) Preparaty do leczenia chorób górnych dróg oddechowych
IL232384A (en) Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
HRP20190169T1 (hr) Postupci liječenja povećanja tjelesne težine inducirane antipsihoticima
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
HRP20181979T1 (hr) Medicinsko ljepilo i postupak njegove proizvodnje
PL3363439T3 (pl) Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej
FR2964854B1 (fr) Gouttieres dentaires universelles
LT2531124T (lt) Prietaisai odos pažeidimams gydyti
IL219298A0 (en) Triptans for the treatment of psoriasis